Rahden Paul, Fatty Abdoulie, Jobarteh Momodou Lamin, Sallah Abdoulwahab, Jaiteh Ebrahim, Allen Angela, Umoh Doreen, Bass Fanta, Dodd Matthew, Howell Carol, Markaryan Elena, Hnatič Radovan, Allen Stephen
Department of Paediatrics, Edward Francis Small Teaching Hospital, Banjul, Gambia.
Department of Implementation Research, Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany.
BMJ Paediatr Open. 2025 Jan 23;9(1):e003133. doi: 10.1136/bmjpo-2024-003133.
Diarrhoea remains a leading cause of death in children. An intestinal adsorbent may reduce diarrhoea duration and severity.
Randomised controlled feasibility trial with two phases: phase 1 (0-4 hours and double-blind) and phase 2 (up to 5 days and open-label). 50 children aged 6-59 months with acute diarrhoea presenting with no or some dehydration to the emergency paediatric unit and outpatient clinic at Edward Francis Small Teaching Hospital, Banjul, The Gambia were randomised to either standard treatment (oral rehydration fluid and zinc) or standard treatment with polymethylsiloxane polyhydrate for up to 5 days.
Recruitment was completed in 7 months. All but one child completed the study. There were no major protocol deviations although patient-held diaries did not collect reliable information. Time from randomisation to the last watery stool (primary outcome) was shorter in the intervention than control arm (mean difference -19.3 hours, 95% CI -30.9 to -7.8). Stool frequency was lower in the intervention arm on days 2 (95% CI -0.8 to -1.3 to -0.3) and 3 (95% CI -0.8; -1.3 to -0.3). One serious event (death) occurred in the control arm.
A randomised, controlled trial is feasible. Further clinical trials are warranted to confirm the efficacy of polymethylsiloxane polyhydrate in acute diarrhoea and inform management guidelines.
PACTR202302683128875.
腹泻仍是儿童死亡的主要原因。肠道吸附剂可能会缩短腹泻持续时间并减轻严重程度。
采用两阶段随机对照可行性试验:第1阶段(0 - 4小时,双盲)和第2阶段(长达5天,开放标签)。在冈比亚班珠尔的爱德华·弗朗西斯·斯莫尔教学医院的急诊儿科病房和门诊诊所,50名年龄在6 - 59个月、患有急性腹泻且无脱水或有轻度脱水的儿童被随机分为两组,一组接受标准治疗(口服补液盐和锌),另一组接受标准治疗加至多5天的聚甲基硅氧烷多水合物治疗。
招募工作在7个月内完成。除一名儿童外,所有儿童均完成了研究。尽管患者日记未收集到可靠信息,但未出现重大方案偏差。干预组从随机分组到最后一次水样便的时间(主要结局)比对照组短(平均差值 -19.3小时,95%置信区间 -30.9至 -7.8)。干预组在第2天(95%置信区间 -0.8至 -1.3至 -0.3)和第3天(95%置信区间 -0.8; -1.3至 -0.3)的粪便频率较低。对照组发生了1起严重事件(死亡)。
随机对照试验是可行的。有必要进行进一步的临床试验,以确认聚甲基硅氧烷多水合物在急性腹泻中的疗效,并为管理指南提供依据。
PACTR202302683128875。